NEW PRODUCT
NEW PRODUCT
co-owned by
Nuvexa Biologix
Nuvexa Biologix provides high-quality, research-grade biologic materials and professional resources for modern medical practices. Co-owned by OmniMedix AVR, our role goes beyond supply—we focus on supporting clinics with reliable access to products, educational resources, and consultation services.
From product information and staff training to logistical support and practice integration, our team is here to assist every step of the way. We simplify the process, provide clear guidance, and ensure your practice has the resources needed to operate with confidence and professionalism.
At OmniMedix AVR, our commitment to personalized service goes beyond fulfillment—we provide access to knowledgeable professionals who support our clients with resources, product information, and best-practice insights. This level of guidance helps practices make confident, informed decisions when exploring and integrating new solutions.
Our agility and responsiveness allow us to stay ahead in a rapidly evolving industry. We continually adapt our services to meet the real-world needs of providers—whether that’s streamlining logistics, ensuring product reliability, or tailoring operational solutions for each practice.
Open, transparent communication is at the core of everything we do. From initial onboarding through ongoing support, we keep our clients informed and equipped. When you partner with OmniMedix AVR, you gain more than a supplier—you gain a collaborative team aligned with your practice’s goals and committed to long-term success.
Products
-
Double-Concentration Cord Blood–Derived Exosomes | hPESC-Based | Verified for Quality and Consistency
Nuvexa 180 builds on the formulation of Nuvexa 90, offering double the concentration of cord blood–derived exosomes per vial. Sourced from human progenitor endothelial stem cells (hPESCs), this product undergoes validation through methods such as ELISA, nanoparticle tracking analysis, and single-particle interferometric reflectance imaging sensing to ensure consistency and integrity.
Each vial demonstrates the presence of a broad matrix of biomolecules, along with membrane-enclosed exosome particles in the expected size range and expressing CD81 and CD9 tetraspanins. These measures confirm both product identity and purity.
Nuvexa 180 reflects our commitment to transparency, rigorous quality standards, and innovation in biologic sciences.
-
100 Billion Exosomes | Wharton’s Jelly–Derived | Liquid Format | Transparent Contents
Quality Innovation in a Ready-to-Use Format
Nuvexa 100 builds on the Nuvexa 50 formulation by providing a higher concentration of Wharton’s Jelly–derived exosomes in a liquid, pre-reconstituted form. This format eliminates the need for reconstitution, offering convenience and consistency for professional use.
The formulation is verified using established analytical methods to confirm exosome identity, size, and purity, with markers such as CD81 and CD9 tetraspanins. Transparent labeling and clear glass packaging reflect our commitment to product integrity and provider confidence.
Nuvexa 100 represents the next step in our ongoing focus on innovation, transparency, and rigorous quality standards in biologic sciences.
-
Cord Blood–Derived Exosomes | hPESC-Based | Quality Verified
Nuvexa 90 contains cord blood–derived exosomes produced from human progenitor endothelial stem cells (hPESCs). Each batch is characterized using established analytical methods, including ELISA, nanoparticle tracking analysis, and interferometric reflectance imaging sensing, to confirm size, identity, and purity.
The formulation demonstrates the presence of a broad profile of biomolecules and exosome markers such as CD81 and CD9 tetraspanins, ensuring product consistency and integrity.
Backed by published research and built on rigorous quality standards, Nuvexa 90 reflects our ongoing commitment to innovation, transparency, and excellence in biologic sciences.
-
50 Billion Lyophilized Exosomes | Wharton’s Jelly–Derived | Shelf-Stable | Transparent Contents
A Foundation in Quality and Science
Nuvexa 50 contains lyophilized exosomes derived from Wharton’s Jelly mesenchymal stem cells (MSCs). This formulation undergoes careful processing and quality checks to preserve structural integrity, ensure purity, and provide consistency in every vial.
Convenient, Shelf-Stable Format
Designed in a lyophilized form, Nuvexa 50 can be stored at room temperature and reconstituted when needed. This format supports ease of handling and integration into professional workflows while maintaining product integrity.
Commitment to Transparency
Every vial is packaged in clear glass with complete ingredient disclosure, reflecting our commitment to transparency and product integrity. Nuvexa 50 represents our dedication to advancing biologic sciences through rigorous quality standards and clear communication with providers.
-
30 Billion Lyophilized Exosomes | Wharton’s Jelly–Derived | Shelf-Stable | Transparent Contents
Quality and Convenience in Every Vial
Nuvexa 30 contains lyophilized exosomes derived from Wharton’s Jelly and formulated at a 30-billion concentration. Each vial is processed using a controlled lyophilization method designed to preserve structure, integrity, and purity.
Shelf-Stable and Easy to Handle
Nuvexa 30 is stable at room temperature, requiring no refrigeration, and is reconstituted when needed. This convenient format supports flexibility in professional workflows while maintaining consistency across batches.
Transparency and Standards
With clear packaging and full ingredient disclosure, Nuvexa 30 reflects our commitment to transparency and product integrity. It offers providers a standardized option backed by rigorous
quality practices in biologic sciences.
Resources
Nuvexa 50 contains 50B Wharton’s Jelly–derived lyophilized exosomes, designed with stability, consistency, and transparency in mind. Developed to support professional use in advanced biologic applications, Nuvexa 50 reflects our commitment to high-quality standards and innovation in the field.
Nuvexa 50
Nuvexa 90
Nuvexa 90 contains 90B Wharton’s Jelly–derived lyophilized exosomes, produced with a focus on purity, stability, and consistency. Developed to align with advanced biologic applications, Nuvexa 90 reflects our commitment to quality standards and innovation.
Nuvexa 100 contains 100B cord blood–derived lyophilized exosomes, produced with an emphasis on quality, consistency, and transparency. Developed to reflect current advancements in biologic science, Nuvexa 100 highlights our commitment to rigorous standards and innovation in the field.
Nuvexa 100
Nuvexa 180 contains 180B cord blood–derived lyophilized exosomes, developed with a focus on quality, consistency, and transparency. Designed to align with the latest advancements in biologic sciences, Nuvexa 180 reflects our commitment to rigorous standards and ongoing innovation.
Nuvexa 180
Disclaimer: These products are not approved by the FDA to diagnose, treat, cure, or prevent any disease. All information is provided for educational purposes only.
NAD+ Infusion Therapy
A Complete Clinical Guide for Providers—your resource for science-backed protocols, dosing, and strategies to boost vitality, cognition, and recovery.
